1. Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology: Can Preoperative 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Replace Pelvic Lymph Node Dissection for Prostate Cancer Staging? J Urol 2019.

2. Prendeville S, Berney DM, Bubendorf L, Comperat E, Egevad L, Hes O, Kristiansen G, Oxley J, van Leenders G, Varma M, van der Kwast T. Handling and Reporting of Pelvic Lymphadenectomy Specimens in Prostate and Bladder Cancer: A Web-based Survey by the European Network of Uropathologists (ENUP). Histopathology 2019.

3. Egevad L, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Kench JG. Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Pathology 2019; 51: 11-20.

4. Egevad L, Delahunt B, Yaxley J, Samaratunga H. Evolution, controversies and the future of prostate cancer grading. Pathol Int 2019.

5. Egevad L, Delahunt B, Samaratunga H, Leite KR, Efremov G, Furusato B, Han M, Jufe L, Tsuzuki T, Wang Z, Hörnblad J, Clements M. The International Society of Urological Pathology Education web - A web-based system for training and testing of pathologists. Virchows Arch 2019; Feb 21. .

6. Delahunt B, Eble JN, Egevad L, Samaratunga H. Grading of renal cell carcinoma. Histopathology 2019; 74: 4-17.

7. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Coughlin G, Dunglison N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Samaratunga H. Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. Histopathology 2019; 74: 284-90.

8. Adamo H, Hammarsten P, Hagglof C, Dahl Scherdin T, Egevad L, Stattin P, Halin Bergstrom S, Bergh A. Prostate cancer induces C/EBPbeta expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome. Prostate 2019; 79: 435-45.

9. Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World J Urol 2018; 36: 15-20.

10. Verrill C, Perry-Keene J, Srigley JR, Zhou M, Humphrey PA, Lopez-Beltran A, Egevad L, Ulbright TM, Tickoo SK, Epstein JI, Comperat E, Berney DM, Members of the ITTP. Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol 2018; 42: e33-e43.

11. Strom P, Nordstrom T, Aly M, Egevad L, Gronberg H, Eklund M. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol 2018; 74: 204-10.

12. Sjoberg E, Frodin M, Lovrot J, Mezheyeuski A, Johansson M, Harmenberg U, Egevad L, Sandstrom P, Ostman A. A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis. Br J Cancer 2018; 119: 840-6.

13. Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, Akre O, Carlsson S, Hosseini A, Olsson M, Egevad L, Wiklund F, Steineck G, Wiklund NP. Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. Eur Urol Focus 2018; 4: 351-9.

14. Nordstrom T, Gronberg H, Adolfsson J, Egevad L, Aly M, Eklund M. Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. Eur Urol Focus 2018; 4: 385-7.

15. Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, De Maeseneer D, Strijbos M, Bols A, Fransis K, Oeyen S, van Dam PJ, Van den Eynden G, Rutten A, Aly M, Nordstrom T, Van Laere S, Rantalainen M, Rajan P, Egevad L, Ullen A, Yachnin J, Dirix L, Gronberg H, Lindberg J. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med 2018; 10: 85.

16. Lindh C, Delahunt B, Samaratunga H, Yaxley J, Gudjonsdottir J, Clements M, Lindberg J, Egevad L. A novel technique for biobanking of large sections of radical prostatectomy specimens. Histopathology 2018; 72: 481-9.

17. Lindh C, Delahunt B, Egevad L. Macroscopic features of prostate cancer. Pathology 2018; 50: 382-8.

18. Kammerer-Jacquet SF, Comperat E, Egevad L, Hes O, Oxley J, Varma M, Kristiansen G, Berney DM. Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP). Virchows Arch 2018; 472: 599-604.

19. Eklund M, Nordstrom T, Aly M, Adolfsson J, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Presti JC, StLezin M, Clements M, Egevad L, Gronberg H. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. Eur Urol Focus 2018; 4: 707-10.

20. Egevad L, Samaratunga H, Delahunt B. Re: Comment on Egevad et al., 'Utility of Pathology Imagebase for standardisation of prostate cancer grading'. Histopathology 2018; 73: 361-2.

21. Egevad L, Delahunt B, Kristiansen G, Samaratunga H, Varma M. Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology 2018; 50: 60-73.

22. Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, Humphrey PA, Hornblad J, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M. Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology 2018; 73: 8-18.

23. Delahunt B, Egevad L, Yaxley J, Samaratunga H. The current status of renal cell carcinoma and prostate carcinoma grading. Int Braz J Urol 2018; 44: 1057-62.

24. Delahunt B, Egevad L, Srigley JR, Samaratunga H. Fuhrman grading is inappropriate for papillary renal cell carcinoma. World J Urol 2018; 36: 1335-6.

25. Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, Stattin P, Widmark A, Bergh A, Wikstrom P. Subgroups of Castration-resistant Prostate Cancer

Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017; 71: 776-87.

26. Williamson SR, Delahunt B, Magi-Galluzzi C, Algaba F, Egevad L, Ulbright TM, Tickoo SK, Srigley JR, Epstein JI, Berney DM, Members of the ITTP. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017; 70: 335-46.

27. Verrill C, Yilmaz A, Srigley JR, Amin MB, Comperat E, Egevad L, Ulbright TM, Tickoo SK, Berney DM, Epstein JI, Members of the International Society of Urological Pathology Testicular Tumor P. Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. Am J Surg Pathol 2017; 41: e22-e32.

28. Varma M, Egevad L, Delahunt B, Kristiansen G. Reply: 'A plea for greater standardization in intraductal carcinoma of the prostate -greater standardization requires greater evidence': let's use the available evidence. Histopathology 2017; 70: 1013-4.

29. Varma M, Egevad L, Delahunt B, Kristiansen G. Reporting intraductal carcinoma of the prostate: a plea for greater standardization. Histopathology 2017; 70: 504-7.

30. Seipel AH, Whitington T, Delahunt B, Samaratunga H, Mayrhofer M, Wiklund P, Gronberg H, Lindberg J, Egevad L. Genetic profile of ductal adenocarcinoma of the prostate. Hum Pathol 2017; 69: 1-7.

31. Scott E, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7. Urol Oncol 2017; 35: 120.

32. Samaratunga H, Delahunt B, Srigley JR, Yaxley J, Johannsen S, Coughlin G, Gianduzzo T, Kua B, Patterson I, Nacey JN, Egevad L. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology 2017; 71: 641-7.

33. Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Gronberg H, Neal DE, CamCa PSG. Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144]. EBioMedicine 2017; 17: 238.

34. Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G, Wiklund NP. Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol 2017; 35: 3566-74.

35. Radestad E, Egevad L, Jorns C, Mattsson J, Sundberg B, Nava S, Ericzon BG, Henningsohn L, Levitsky V, Uhlin M. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget 2017; 8: 60257-69.

36. Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, Fradet Y, Tetu B, Lindberg J, Egevad L, Gronberg H, Ross-Adams H, Lamb AD, Halim S, Dunning MJ, Neal DE, Pintilie M, van der Kwast T, Bristow RG, Boutros PC.

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. Eur Urol 2017; 72: 22-31.

37. Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, Stattin P, Egevad L. Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology 2017; 49: 715-20.

38. Idrees MT, Ulbright TM, Oliva E, Young RH, Montironi R, Egevad L, Berney D, Srigley JR, Epstein JI, Tickoo SK, Members of the International Society of Urological Pathology Testicular Tumour P. The World Health Organization 2016 classification of testicular non-germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017; 70: 513-21.

39. Frodin M, Mezheyeuski A, Corvigno S, Harmenberg U, Sandstrom P, Egevad L, Johansson M, Ostman A. Perivascular PDGFR-beta is an independent marker for prognosis in renal cell carcinoma. Br J Cancer 2017; 116: 195-201.

40. Egevad L, Samaratunga H, Srigley JR, Delahunt B. Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. Eur Urol 2017; 71: e52-e3.

41. Egevad L, Samaratunga H, Delahunt B. Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. Int J Urol 2017; 24: 286-7.

42. Egevad L, Cheville J, Evans AJ, Hornblad J, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, Pan CC, Samaratunga H, Srigley JR, True L, Zhou M, Clements M, Delahunt B, Panel IPIE. Pathology Imagebase-a reference image database for standardization of pathology. Histopathology 2017; 71: 677-85.

43. Egevad L. Editorial Comment. J Urol 2017; 197: 81-2.44. Delahunt B, Samaratunga H, Egevad L. The decline of medical publishing: the rise of

the pseudo-journal. Pathology 2017; 49: 673-4.45. Delahunt B, Grignon DJ, Samaratunga H, Srigley JR, Leite KR, Kristiansen G, Evans

AJ, Kench JG, Egevad L. Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Arch Pathol Lab Med 2017; 141: 182-3.

46. Delahunt B, Egevad L, Samaratunga H, Varma M, Verrill C, Cheville J, Kristiansen G, Corbishley C, Berney DM. UICC drops the ball in the 8th edition TNM staging of urological cancers. Histopathology 2017; 71: 5-11.

47. Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L. Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012. BJU Int 2017; 119: 50-6.

48. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J, Samaratunga H. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology 2017; 71: 918-25.

49. Cheteh EH, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L, Bykov VJ, Ostman A, Wiman KG. Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death Dis 2017; 8: e2848.

50. Arseneault M, Monlong J, Vasudev NS, Laskar RS, Safisamghabadi M, Harnden P, Egevad L, Nourbehesht N, Panichnantakul P, Holcatova I, Brisuda A, Janout V, Kollarova H, Foretova L, Navratilova M, Mates D, Jinga V, Zaridze D, Mukeria A,

Jandaghi P, Brennan P, Brazma A, Tost J, Scelo G, Banks RE, Lathrop M, Bourque G, Riazalhosseini Y. Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma. Sci Rep 2017; 7: 44876.

51. Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, Keck B, Pizzolitto S, Sioletic S, Wullich B, Hartmann A. Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency. Am J Surg Pathol 2017; 41: 253-62.

52. Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, Svezia I, Klevebring D, Mills IG, Karlsson R, Halim S, Dunning MJ, Egevad L, Warren AY, Neal DE, Gronberg H, Lindberg J, Wei GH, Wiklund F. Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nat Genet 2016; 48: 387-97.

53. Varma M, Egevad L, Algaba F, Berney D, Bubendorf L, Camparo P, Comperat E, Erbersdobler A, Griffiths D, Grobholz R, Haitel A, Hulsbergen-van de Kaa C, Langner C, Loftus B, Lopez-Beltran A, Mayer N, Nesi G, Oliveira P, Oxley J, Rioux-Leclercq N, Seitz G, Shanks J, Kristiansen G. Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. J Clin Pathol 2016; 69: 852-7.

54. Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol 2016; 114: 664-70.

55. Srigley JR, Delahunt B, Egevad L, Samaratunga H, Yaxley J, Evans AJ. One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Can Urol Assoc J 2016; 10: 339-41.

56. Seipel AH, Samaratunga H, Delahunt B, Wiklund P, Clements M, Egevad L. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study. APMIS 2016; 124: 263-70.

57. Seipel AH, Delahunt B, Samaratunga H, Egevad L. Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology 2016; 48: 398-405.

58. Samaratunga H, Delahunt B, Yaxley J, Srigley JR, Egevad L. From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scand J Urol 2016; 50: 325-9.

59. Samaratunga H, Delahunt B, Egevad L, Srigley JR, Yaxley J. The evolution of Gleason grading of prostate cancer. Journal of Diagnostic Pathology 2016; 11: 5-11.

60. Samaratunga H, Delahunt B, Egevad L, Adamson M, Hussey D, Malone G, Hoyle K, Nathan T, Kerle D, Ferguson P, Nacey JN. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation. Histopathology 2016; 68: 533-40.

61. Mezheyeuski A, Hrynchyk I, Karlberg M, Portyanko A, Egevad L, Ragnhammar P, Edler D, Glimelius B, Ostman A. Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. Sci Rep 2016; 6: 36149.

62. Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. Eur Urol 2016; 69: 1135-41.

63. Kweldam CF, Nieboer D, Algaba F, Amin MB, Berney DM, Billis A, Bostwick DG, Bubendorf L, Cheng L, Comperat E, Delahunt B, Egevad L, Evans AJ, Hansel DE,

Humphrey PA, Kristiansen G, van der Kwast TH, Magi-Galluzzi C, Montironi R, Netto GJ, Samaratunga H, Srigley JR, Tan PH, Varma M, Zhou M, van Leenders GJ. Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology 2016; 69: 441-9.

64. Kristiansen G, Egevad L, Amin M, Delahunt B, Srigley JR, Humphrey PA, Epstein JI, Graduierungskommittee. [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma]. Pathologe 2016; 37: 17-26.

65. Iglesias-Gato D, Wikstrom P, Tyanova S, Lavallee C, Thysell E, Carlsson J, Hagglof C, Cox J, Andren O, Stattin P, Egevad L, Widmark A, Bjartell A, Collins CC, Bergh A, Geiger T, Mann M, Flores-Morales A. The Proteome of Primary Prostate Cancer. Eur Urol 2016; 69: 942-52.

66. Hammarsten P, Dahl Scherdin T, Hagglof C, Andersson P, Wikstrom P, Stattin P, Egevad L, Granfors T, Bergh A. High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting. PLoS One 2016; 11: e0164016.

67. Haldrup C, Lynnerup AS, Storebjerg TM, Vang S, Wild P, Visakorpi T, Arsov C, Schulz WA, Lindberg J, Gronberg H, Egevad L, Borre M, Orntoft TF, Hoyer S, Sorensen KD. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Mol Oncol 2016; 10: 825-37.

68. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol 2016; 69: 428-35.

69. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading C. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 2016; 40: 244-52.

70. Egevad L, Samaratunga H, Srigley JR, Delahunt B, Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason Grade. BJU Int 2016; 118: E1-2.

71. Egevad L, Samaratunga H, Srigley JR, Delahunt B. In Regard to Zietman et al. Int J Radiat Oncol Biol Phys 2016; 96: 1126-7.

72. Egevad L, Samaratunga H, Srigley JR, Delahunt B. New Gleason grading system: Statement from the editors of 6 journals. Urol Oncol 2016; 34: 479-80.

73. Egevad L, Samaratunga H, Srigley JR, Delahunt B. Reply by the Authors. Urology 2016; 96: 179-80.

74. Egevad L, Samaratunga H, Srigley JR, Delahunt B. Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade: A. Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr. J Urol 2016;195: 1723. J Urol 2016; 196: 1321-3.

75. Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading. APMIS 2016; 124: 433-5.

76. Egevad L, Delahunt B, Samaratunga H, Srigley JR. Utility of Reporting the Percentage of High-grade Prostate Cancer. Eur Urol 2016; 69: 599-600.

77. Egevad L, Delahunt B, Evans AJ, Grignon DJ, Kench JG, Kristiansen G, Leite KR, Samaratunga H, Srigley JR. International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. Am J Surg Pathol 2016; 40: 858-61.

78. Egevad L. Editorial Comment. J Urol 2016; 195: 1420.

79. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Reply: Gleason and Fuhrman no longer make the grade. Histopathology 2016; 69: 341-2.

80. Delahunt B, Egevad L, Samaratunga H, Martignoni G, Nacey JN, Srigley JR. Gleason and Fuhrman no longer make the grade. Histopathology 2016; 68: 475-81.

81. Delahunt B, Egevad L, Grignon DJ, Srigley JR, Samaratunga H. Prostate cancer grading: recent developments and future directions. BJU Int 2016; 117 Suppl 4: 7-8.

82. Zhou M, Li J, Cheng L, Egevad L, Deng FM, Kunju LP, Magi-Galluzzi C, Melamed J, Mehra R, Mendrinos S, Osunkoya AO, Paner G, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang X, Shah RB. Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy: An Interobserver Reproducibility Study Among Urologic Pathologists With Recommendations. Am J Surg Pathol 2015; 39: 1331-9.

83. Sooriakumaran P, Ploumidis A, Nyberg T, Olsson M, Akre O, Haendler L, Egevad L, Nilsson A, Carlsson S, Jonsson M, Adding C, Hosseini A, Steineck G, Wiklund P. The impact of length and location of positive margins in predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years. BJU Int 2015; 115: 106-13.

84. Shah RB, Li J, Cheng L, Egevad L, Deng FM, Fine SW, Kunju LP, Melamed J, Mehra R, Osunkoya AO, Paner GP, Shen SS, Tsuzuki T, Trpkov K, Tian W, Yang XJ, Zhou M. Diagnosis of Gleason pattern 5 prostate adenocarcinoma on core needle biopsy: an interobserver reproducibility study among urologic pathologists. Am J Surg Pathol 2015; 39: 1242-9.

85. Samaratunga H, Delahunt B, Gianduzzo T, Coughlin G, Duffy D, LeFevre I, Johannsen S, Egevad L, Yaxley J. The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology 2015; 47: 515-9.

86. Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Gronberg H, Neal DE, CamCa PSG. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine 2015; 2: 1133-44.

87. Nilsson M, Hagglof C, Hammarsten P, Thysell E, Stattin P, Egevad L, Granfors T, Jernberg E, Wikstrom P, Halin Bergstrom S, Bergh A. High Lysyl Oxidase (LOX) in the Non-Malignant Prostate Epithelium Predicts a Poor Outcome in Prostate Cancer Patient Managed by Watchful Waiting. PLoS One 2015; 10: e0140985.

88. Lundholm M, Hagglof C, Wikberg ML, Stattin P, Egevad L, Bergh A, Wikstrom P, Palmqvist R, Edin S. Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions. Sci Rep 2015; 5: 15651.

89. Lindberg J, Kristiansen A, Wiklund P, Gronberg H, Egevad L. Tracking the origin of metastatic prostate cancer. Eur Urol 2015; 67: 819-22.

90. Kristiansen G, Delahunt B, Srigley JR, Luders C, Lunkenheimer JM, Gevensleben H, Thiesler T, Montironi R, Egevad L. [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)]. Pathologe 2015; 36: 310-6.

91. Kharaziha P, Chioureas D, Baltatzis G, Fonseca P, Rodriguez P, Gogvadze V, Lennartsson L, Bjorklund AC, Zhivotovsky B, Grander D, Egevad L, Nilsson S, Panaretakis T. Sorafenib-induced defective autophagy promotes cell death by necroptosis. Oncotarget 2015; 6: 37066-82.

92. Iglesias-Gato D, Chuan YC, Jiang N, Svensson C, Bao J, Shang Z, Paul I, Egevad L, Kessler BM, Wikstrom P, Niu Y, Flores-Morales A. Erratum: OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol Cancer 2015; 14: 88.

93. Iglesias-Gato D, Chuan YC, Jiang N, Svensson C, Bao J, Paul I, Egevad L, Kessler BM, Wikstrom P, Niu Y, Flores-Morales A. OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol Cancer 2015; 14: 8.

94. Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol 2015; 16: 1667-76.

95. Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology 2015; 47: 1-3.

96. Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, Matthews J, Duchesne G, Spry NA, Christie D, Joseph D, Attia J, Denham JW. Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data. Pathology 2015; 47: 520-5.

97. Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 1998-2011: a registry study of 97,168 men. BJU Int 2015; 115: 248-55.

98. Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Upper limit of cancer extent on biopsy defining very low-risk prostate cancer. BJU Int 2015; 116: 213-9.

99. Berney DM, Algaba F, Amin M, Delahunt B, Comperat E, Epstein JI, Humphrey P, Idrees M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Oliva E, Srigley J, Reuter VE, Trpkov K, Ulbright TM, Varma M, Verrill C, Young RH, Zhou M, Egevad L. Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. Histopathology 2015; 67: 313-24.

100. Alexeyenko A, Alkasalias T, Pavlova T, Szekely L, Kashuba V, Rundqvist H, Wiklund P, Egevad L, Csermely P, Korcsmaros T, Guven H, Klein G. Confrontation of fibroblasts with cancer cells in vitro: gene network analysis of transcriptome changes and differential capacity to inhibit tumor growth. J Exp Clin Cancer Res 2015; 34: 62.

101. Whitaker HC, Shiong LL, Kay JD, Gronberg H, Warren AY, Seipel A, Wiklund F, Thomas B, Wiklund P, Miller JL, Menon S, Ramos-Montoya A, Vowler SL, Massie C, Egevad L, Neal DE. N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype. Oncogene 2014; 33: 5274-87.

102. Tidehag V, Hammarsten P, Egevad L, Granfors T, Stattin P, Leanderson T, Wikstrom P, Josefsson A, Hagglof C, Bergh A. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome. Eur J Cancer 2014; 50: 1829-35.

103. Srigley JR, Delahunt B, Egevad L, Samaratunga H, Evans AJ. Optimising pre-analytical factors affecting quality of prostate biopsies: the case for site specific labelling and single core submission. Pathology 2014; 46: 579-80.

104. Seipel AH, Samaratunga H, Delahunt B, Wiklund F, Wiklund P, Lindberg J, Gronberg H, Egevad L. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Arch 2014; 465: 559-65.

105. Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, Humphrey PA, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S, Egevad L. Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology 2014; 65: 216-27.

106. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzalez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanche H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 2014; 5: 5135.

107. Samaratunga H, Delahunt B, Yaxley J, Perry-Keene J, Lamb DS, Srigley JR, Egevad L, Nacey JN. Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. Pathology 2014; 46: 11-4.

108. Rioux-Leclercq N, Ferran A, Mahul A, Argani P, Billis A, Bonsib S, Cheng L, Cheville J, Eble J, Egevad L, Epstein J, Grignon D, Hes O, Humphrey P, Magi-Galluzzi C, Martignoni G, McKenney J, Merino M, Moch H, Montironi R, Netto G, Reuter V, Samaratunga H, Shen S, Srigley J, Tamboli P, Tan PH, Tickoo S, Trpkov K, Zhou M, Delahunt B, Comperat E, International Society of Urologic P. [Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations]. Ann Pathol 2014; 34: 448-61.

109. Norstrom MM, Radestad E, Stikvoort A, Egevad L, Bergqvist M, Henningsohn L, Mattsson J, Levitsky V, Uhlin M. Novel method to characterize immune cells from human prostate tissue. Prostate 2014; 74: 1391-9.

110. Nordstrom T, Aly M, Eklund M, Egevad L, Gronberg H. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml. Eur Urol 2014; 65: 1184-90.

111. Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB, College of American P, International Society of Urological P, Association of Directors of A, Surgical P. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch 2014; 465: 623-8.

112. Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH. Biomarkers in renal cancer. Virchows Arch 2014; 464: 359-65.

113. Miyai K, Kristiansen A, Egevad L, Pina-Oviedo S, Divatia MK, Shen SS, Miles BJ, Ayala AG, Park YW, Ro JY. Seminal vesicle intraepithelial involvement by

prostate cancer: putative mechanism and clinicopathological significance. Hum Pathol 2014; 45: 1805-12.

114. Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Gronberg H, Hoyer S, Borre M, Orntoft TF, Sorensen KD. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res 2014; 20: 2169-81.

115. Klevebring D, Neiman M, Sundling S, Eriksson L, Darai Ramqvist E, Celebioglu F, Czene K, Hall P, Egevad L, Gronberg H, Lindberg J. Evaluation of exome sequencing to estimate tumor burden in plasma. PLoS One 2014; 9: e104417.

116. Iglesias-Gato D, Chuan YC, Wikstrom P, Augsten S, Jiang N, Niu Y, Seipel A, Danneman D, Vermeij M, Fernandez-Perez L, Jenster G, Egevad L, Norstedt G, Flores-Morales A. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis 2014; 35: 24-33.

117. Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, Camparo P, Cheng L, Clouston D, Comperat EM, Datta MW, Evans AG, Griffiths DF, Guo CC, Hailemariam S, Huang W, Humphrey PA, Jiang Z, Kahane H, Kristiansen G, La Rosa FG, Lopez-Beltran A, MacLennan GT, Magi-Galluzzi C, Merrimen J, Montironi R, Osunkoya AO, Picken MM, Rao N, Shah RB, Shanks JH, Shen SS, Tawfik OW, True LD, Van der Kwast T, Varma M, Wheeler TM, Zynger DL, Sahr N, Bostwick DG. Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. Ann Diagn Pathol 2014; 18: 333-42.

118. Huang Q, Whitington T, Gao P, Lindberg JF, Yang Y, Sun J, Vaisanen MR, Szulkin R, Annala M, Yan J, Egevad LA, Zhang K, Lin R, Jolma A, Nykter M, Manninen A, Wiklund F, Vaarala MH, Visakorpi T, Xu J, Taipale J, Wei GH. A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. Nat Genet 2014; 46: 126-35.

119. Hammarsten P, Winther J, Rudolfsson SH, Haggstrom J, Karalija A, Egevad L, Granfors T, Fowler CJ. ErbB2 receptor immunoreactivity in prostate cancer: relationship to the androgen receptor, disease severity at diagnosis and disease outcome. PLoS One 2014; 9: e105063.

120. Hagglof C, Hammarsten P, Stromvall K, Egevad L, Josefsson A, Stattin P, Granfors T, Bergh A. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS One 2014; 9: e86824.

121. Epstein JI, Egevad L, Humphrey PA, Montironi R, Members of the IIiDUPG. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 2014; 38: e6-e19.

122. Egevad G, Petkova VY, Vilholm OJ. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin. J Parkinsons Dis 2014; 4: 321-6.

123. Delahunt B, Srigley JR, Montironi R, Egevad L. Advances in renal neoplasia: recommendations from the 2012 International Society of Urological Pathology Consensus Conference. Urology 2014; 83: 969-74.

124. Delahunt B, Srigley JR, Egevad L, Montironi R, International Society for Urological P. International Society of Urological Pathology grading and other prognostic factors for renal neoplasia. Eur Urol 2014; 66: 795-8.

125. Bruzzese F, Hagglof C, Leone A, Sjoberg E, Roca MS, Kiflemariam S, Sjoblom T, Hammarsten P, Egevad L, Bergh A, Ostman A, Budillon A, Augsten M. Local and

systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. Cancer Res 2014; 74: 3408-17.

126. Berney DM, Algaba F, Camparo P, Comperat E, Griffiths D, Kristiansen G, Lopez-Beltran A, Montironi R, Varma M, Egevad L. Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. Virchows Arch 2014; 464: 583-7.

127. Berney DM, Algaba F, Camparo P, Comperat E, Griffiths D, Kristiansen G, Lopez-Beltran A, Montironi R, Varma M, Egevad L. The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists. Histopathology 2014; 64: 405-11.

128. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med 2014; 138: 1387-405.

129. Amin MB, Epstein JI, Ulbright TM, Humphrey PA, Egevad L, Montironi R, Grignon D, Trpkov K, Lopez-Beltran A, Zhou M, Argani P, Delahunt B, Berney DM, Srigley JR, Tickoo SK, Reuter VE, Members of the IIiDUPG. Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference. Am J Surg Pathol 2014; 38: 1017-22.

130. Varma M, Berney DM, Algaba F, Camparo P, Comperat E, Griffiths DF, Kristiansen G, Lopez-Beltran A, Montironi R, Egevad L. Prostate needle biopsy processing: a survey of laboratory practice across Europe. J Clin Pathol 2013; 66: 120-3.

131. Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR, members of the IRTP. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol 2013; 37: 1505-17.

132. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H, Panel IRT. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol 2013; 37: 1518-31.

133. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P, Panel IRT. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 2013; 37: 1469-89.

134. Seipel AH, Wiklund F, Wiklund NP, Egevad L. Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch 2013; 462: 429-36.

135. Samaratunga H, Martignoni G, Egevad L, Delahunt B. Premalignant lesions of the urinary bladder. Pathology 2013; 45: 243-50.

136. Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A, Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen MT. Nuclear

Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Hum Pathol 2013; 44: 310-9.

137. Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L, Wang Z, Zhang Z, Sun J, Sun J, Koty PP, Kader AK, Cramer SD, Bova GS, Zheng SL, Gronberg H, Isaacs WB, Xu J. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer 2013; 119: 2405-12.

138. Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, Wikstrom P, Wiklund P, Wiklund F, Egevad L, Gronberg H. The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol 2013; 63: 702-8.

139. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund F, Mills IG, Egevad L, Gronberg H. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 2013; 63: 347-53.

140. Kristiansen A, Wiklund F, Wiklund P, Egevad L. Prognostic significance of patterns of seminal vesicle invasion in prostate cancer. Histopathology 2013; 62: 1049-56.

141. Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Comperat E, Evans AJ, Griffiths D, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Moss S, Oliveira P, Vainer B, Varma M, Camparo P. Standardization of Gleason grading among 337 European pathologists. Histopathology 2013; 62: 247-56.

142. Delahunt B, Egevad L, Montironi R, Srigley JR. International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. Am J Surg Pathol 2013; 37: 1463-8.

143. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR, Members of the IRTP. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013; 37: 1490-504.

144. Danneman D, Wiklund F, Wiklund NP, Egevad L. Prognostic significance of histopathological features of extraprostatic extension of prostate cancer. Histopathology 2013; 63: 580-9.

145. Comperat E, Egevad L, Lopez-Beltran A, Camparo P, Algaba F, Amin M, Epstein JI, Hamberg H, Hulsbergen-van de Kaa C, Kristiansen G, Montironi R, Pan CC, Heloir F, Treurniet K, Sykes J, Van der Kwast TH. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology 2013; 63: 756-66.

146. Comperat E, Camparo P, Srigley J, Delahunt B, Egevad L, Group ICW. [International Society of Urological Pathology (ISUP) Consensus Conference on handling and staging of radical prostatectomy specimens]. Ann Pathol 2013; 33: 155-61.

147. Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI. Contemporary grading for prostate cancer: implications for patient care. Eur Urol 2013; 63: 892-901.

148. Al-Ubaidi FL, Schultz N, Loseva O, Egevad L, Granfors T, Helleday T. Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res 2013; 19: 1547-56.

149. Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A, Carlsson S, Hosseini A, Adding C, Jonsson M, Ploumidis A, Egevad L, Steineck G, Wiklund P. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. Eur Urol 2012; 62: 768-74.

150. Ros MM, Bueno-de-Mesquita HB, Kampman E, Buchner FL, Aben KK, Egevad L, Overvad K, Tjonneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Kaaks R, Teucher B, Weikert S, von Ruesten A, Trichopoulou A, Naska A, Benetou V, Saieva C, Pala V, Ricceri F, Tumino R, Mattiello A, Peeters PH, van Gils CH, Gram IT, Engeset D, Chirlaque MD, Ardanazx E, Rodriguez L, Amanio P, Gonzalez CA, Sanchez MJ, Ulmert D, Ernstrom R, Ljungberg B, Allen NE, Key TJ, Khaw KT, Wareham N, Slimani N, Romieu I, Kiemeney LA, Riboli E. Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. Eur J Cancer 2012; 48: 3267-77.

151. Ros MM, Bueno-de-Mesquita HB, Kampman E, Aben KK, Buchner FL, Jansen EH, van Gils CH, Egevad L, Overvad K, Tjonneland A, Roswall N, Boutron-Ruault MC, Kvaskoff M, Perquier F, Kaaks R, Chang-Claude J, Weikert S, Boeing H, Trichopoulou A, Lagiou P, Dilis V, Palli D, Pala V, Sacerdote C, Tumino R, Panico S, Peeters PH, Gram IT, Skeie G, Huerta JM, Barricarte A, Quiros JR, Sanchez MJ, Buckland G, Larranaga N, Ehrnstrom R, Wallstrom P, Ljungberg B, Hallmans G, Key TJ, Allen NE, Khaw KT, Wareham N, Brennan P, Riboli E, Kiemeney LA. Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2012; 96: 902-10.

152. Montironi R, Srigley JR, Egevad L, Delahunt B. Recent advances in urological pathology. Anal Quant Cytopathol Histpathol 2012; 34: 293-5.

153. Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST, Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Gronberg H, Isaacs WB, Xu J. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 2012; 31: 3939-48.

154. Kristiansen G, Srigley JR, Delahunt B, Egevad L, Internationalen Gesellschaft fur Urologische P. [Diagnostics of radical prostatectomy specimens. Results of the 2009 consensus conference of the International Society of Urological Pathology]. Pathologe 2012; 33: 337-44.

155. Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, Lindberg J, Egevad L, Gronberg H, Isaacs WB, Xu J. Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One 2012; 7: e48455.

156. Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Bjorklund AC, Augsten M, Ullen A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis 2012; 3: e262.

157. Khaja AS, Egevad L, Helczynski L, Wiklund P, Andersson T, Bjartell A. Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer. Cancer Med 2012; 1: 96-104.

158. Josefsson A, Wikstrom P, Egevad L, Granfors T, Karlberg L, Stattin P, Bergh A. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol 2012; 46: 247-57.

159. He H, Delahunt B, Srigley JR, Egevad L, Montironi R, Zhou M. International Society of Urological Pathology Consensus on renal neoplasms. . J Clin Exp Pathol 2012; 30: 591-4.

160. Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, Granfors T, Fowler CJ. Phospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS One 2012; 7: e47994.

161. Fine SW, Amin MB, Berney DM, Bjartell A, Egevad L, Epstein JI, Humphrey PA, Magi-Galluzzi C, Montironi R, Stief C. A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol 2012; 62: 20-39.

162. Egevad L, Mazzucchelli R, Montironi R. Implications of the International Society of Urological Pathology modified Gleason grading system. Arch Pathol Lab Med 2012; 136: 426-34.

163. Egevad L. [The pathologist's role: to diagnose prostatic cancer and determine prognosis]. Lakartidningen 2012; 109: 403-6.

164. Egevad L. Handling of radical prostatectomy specimens. Histopathology 2012; 60: 118-24.

165. Delahunt B, Srigley JR, Montironi R, Egevad L. Urological pathology comes of age. Pathology 2012; 44: 389-90.

166. Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol 2012; 46: 405-10.

167. Camparo P, Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Comperat E, Evans AJ, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A, Montironi R, Oliveira P, Vainer B, Varma M. Utility of whole slide imaging and virtual microscopy in prostate pathology. APMIS 2012; 120: 298-304.

168. Algaba F, Delahunt B, Berney DM, Camparo P, Comperat E, Griffiths D, Kristiansen G, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, Varma M, Egevad L. Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology. J Clin Pathol 2012; 65: 106-13.

169. Al-Ubaidi FL, Schultz N, Egevad L, Granfors T, Helleday T. Castration therapy of prostate cancer results in downregulation of HIF-1alpha levels. Int J Radiat Oncol Biol Phys 2012; 82: 1243-8.

170. van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B, Group IPC. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011; 24: 16-25.

171. Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, Bergh A, Hedman H. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer 2011; 128: 2843-52.

172. Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI, Group IPC. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol 2011; 24: 48-57.

173. Talvitie H, Astrom K, Larsson O, Ahlen J, Bergh A, Egevad L. Solitary fibrous tumor of the prostate: a report of two cases. Pathol Int 2011; 61: 536-8.

174. Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L, Group IPC. International Society of Urological Pathology (ISUP) Consensus Conference on

Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 2011; 24: 6-15.

175. Ros MM, Bas Bueno-de-Mesquita HB, Buchner FL, Aben KK, Kampman E, Egevad L, Overvad K, Tjonneland A, Roswall N, Clavel-Chapelon F, Kaaks R, Chang-Claude J, Boeing H, Weikert S, Trichopoulou A, Orfanos P, Stasinopulou G, Saieva C, Krogh V, Vineis P, Tumino R, Mattiello A, Peeters PH, van Duijnhoven FJ, Lund E, Gram IT, Chirlaque MD, Barricarte A, Rodriguez L, Molina E, Gonzalez C, Dorronsoro M, Manjer J, Ehrnstrom R, Ljungberg B, Allen NE, Roddam AW, Khaw KT, Wareham N, Boffetta P, Slimani N, Michaud DS, Kiemeney LA, Riboli E. Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2011; 128: 2695-708.

176. Montironi R, Egevad L, Bjartell A, Berney DM. Role of histopathology and molecular markers in the active surveillance of prostate cancer. Acta Oncol 2011; 50 Suppl 1: 56-60.

177. Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA, Group IPC. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 2011; 24: 26-38.

178. Lopez-Beltran A, Algaba F, Berney DM, Boccon-Gibod L, Camparo P, Griffiths D, Mikuz G, Montironi R, Varma M, Egevad L. Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology 2011; 58: 579-85.

179. Kench JG, Clouston DR, Delprado W, Eade T, Ellis D, Horvath LG, Samaratunga H, Stahl J, Stapleton AM, Egevad L, Srigley JR, Delahunt B. Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology 2011; 43: 410-9.

180. Josefsson A, Adamo H, Hammarsten P, Granfors T, Stattin P, Egevad L, Laurent AE, Wikstrom P, Bergh A. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome. Am J Pathol 2011; 179: 1961-8.

181. Jaraj SJ, Augsten M, Haggarth L, Wester K, Ponten F, Ostman A, Egevad L. GAD1 is a biomarker for benign and malignant prostatic tissue. Scand J Urol Nephrol 2011; 45: 39-45.

182. Jakszyn P, Gonzalez CA, Lujan-Barroso L, Ros MM, Bueno-de-Mesquita HB, Roswall N, Tjonneland AM, Buchner FL, Egevad L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud MS, Chang-Claude J, Allen NE, Kiemeney LA, Key TJ, Kaaks R, Boeing H, Weikert S, Trichopoulou A, Oikonomou E, Zylis D, Palli D, Berrino F, Vineis P, Tumino R, Mattiello A, Peeters PH, Parr CL, Gram IT, Skeie G, Sanchez MJ, Larranaga N, Ardanaz E, Navarro C, Rodriguez L, Ulmert D, Ehrnstrom R, Hallmans G, Ljungberg B, Roddam AW, Bingham SA, Khaw KT, Slimani N, Boffetta PA, Jenab M, Mouw T, Michaud DS, Riboli E. Red meat, dietary nitrosamines, and heme iron and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 2011; 20: 555-9.

183. Haggarth L, Hagglof C, Jaraj SJ, Wester K, Ponten F, Ostman A, Egevad L. Diagnostic biomarkers of prostate cancer. Scand J Urol Nephrol 2011; 45: 60-7.

184. Egevad L, Srigley JR, Delahunt B. International society of urological pathology consensus conference on handling and staging of radical prostatectomy specimens. Adv Anat Pathol 2011; 18: 301-5.

185. Egevad L, Srigley JR, Delahunt B. International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens: rationale and organization. Mod Pathol 2011; 24: 1-5.

186. Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Comperat E, Evans AJ, Grobholz R, Kristiansen G, Langner C, Lockwood G, Lopez-Beltran A, Montironi R, Oliveira P, Schwenkglenks M, Vainer B, Varma M, Verger V, Camparo P. Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. Virchows Arch 2011; 459: 175-82.

187. Egevad L. Handling and reporting of radical prostatectomy specimens Diagnostic Histopathology 2011; 17: 428-33.

188. Egevad L. Handling of radical prostatectomy specimens: total or partial embedding? Histopathology 2011; 59: 1011-2; author reply 2-3.

189. Chargari C, Comperat E, Magne N, Vedrine L, Houlgatte A, Egevad L, Camparo P. Prostate needle biopsy examination by means of virtual microscopy. Pathol Res Pract 2011; 207: 366-9.

190. Buchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, Tjonneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Kaaks R, Chang-Claude J, Boeing H, Weikert S, Trichopoulou A, Naska A, Benetou V, Palli D, Sieri S, Vineis P, Tumino R, Panico S, van Duijnhoven FJ, Peeters PH, van Gils CH, Lund E, Gram IT, Sanchez MJ, Jakszyn P, Larranaga N, Ardanaz E, Navarro C, Rodriguez L, Manjer J, Ehrnstrom R, Hallmans G, Ljungberg B, Key TJ, Allen NE, Khaw KT, Wareham N, Slimani N, Jenab M, Boffetta P, Kiemeney LA, Riboli E. Variety in vegetable and fruit consumption and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011; 128: 2971-9.

191. Bjartell A, Montironi R, Berney DM, Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 2011; 50 Suppl 1: 76-84.

192. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR, Group IPC. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol 2011; 24: 39-47.

193. Berney DM, Montironi R, Egevad L. Pathology in prostate research: optimizing tissue quality. Acta Oncol 2011; 50 Suppl 1: 53-5.

194. Berney DM, Montironi R, Egevad L. Pathology in prostate research: optimizing the pathological data. Acta Oncol 2011; 50 Suppl 1: 49-52.

195. Valdman A, Jaraj SJ, Comperat E, Charlotte F, Roupret M, Pisa P, Egevad L. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS 2010; 118: 360-5.

196. Thors L, Bergh A, Persson E, Hammarsten P, Stattin P, Egevad L, Granfors T, Fowler CJ. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PLoS One 2010; 5: e12275.

197. Lopez-Beltran A, Montironi R, Egevad L, Caballero-Vargas MT, Scarpelli M, Kirkali Z, Cheng L. Genetic profiles in renal tumors. Int J Urol 2010; 17: 6-19.

198. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, Stattin P, Egevad L, Granfors T, Wikstrom P, Bergh A. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010; 177: 1031-41.

199. Jaraj SJ, Egevad L. Formalin fixation and immunoreactivity in prostate cancer and benign prostatic tissues. APMIS 2010; 118: 383-8.

200. Holmstrom B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Hugosson J, Stattin P, National Prostate Cancer Register of S. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol 2010; 184: 1322-7.

201. Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikstrom P, Egevad L, Granfors T, Stattin P, Bergh A. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 2010; 16: 1245-55.

202. Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC, Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG, Hantz O, Caron de Fromentel C, Chemin IA, Hainaut PL. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis 2010; 31: 1475-82.

203. Egevad L, Valdman A, Wiklund NP, Seve P, Dumontet C. Beta-tubulin III expression in prostate cancer. Scand J Urol Nephrol 2010; 44: 371-7.

204. Comperat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A, Jonmarker S, Capron F, Cussenot O, Charlotte F. Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma. Anal Quant Cytol Histol 2010; 32: 39-44.

205. Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ, Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A. Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes Control 2010; 21: 1523-31.

206. Valdman A, Haggarth L, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, Egevad L. Expression of redox pathway enzymes in human prostatic tissue. Anal Quant Cytol Histol 2009; 31: 367-74.

207. Suzuki R, Allen NE, Key TJ, Appleby PN, Tjonneland A, Johnsen NF, Jensen MK, Overvad K, Boeing H, Pischon T, Kaaks R, Rohrmann S, Trichopoulou A, Misirli G, Trichopoulos D, Bueno-de-Mesquita HB, van Duijnhoven F, Sacerdote C, Pala V, Palli D, Tumino R, Ardanaz E, Quiros JR, Larranaga N, Sanchez MJ, Tormo MJ, Jakszyn P, Johansson I, Stattin P, Berglund G, Manjer J, Bingham S, Khaw KT, Egevad L, Ferrari P, Jenab M, Riboli E. A prospective analysis of the association between dietary fiber intake and prostate cancer risk in EPIC. Int J Cancer 2009; 124: 245-9.

208. Srigley JR, Humphrey PA, Amin MB, Chang SS, Egevad L, Epstein JI, Grignon DJ, McKiernan JM, Montironi R, Renshaw AA, Reuter VE, Wheeler TM, Members of the Cancer Committee CoAP. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 2009; 133: 1568-76.

209. Rosenblatt R, Valdman A, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, Egevad L. Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia. Anal Quant Cytol Histol 2009; 31: 137-42.

210. Reschner A, Harlin H, Laven B, Eriksson F, Pisa P, Egevad L. Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Anal Quant Cytol Histol 2009; 31: 74-82.

211. Johnsen NF, Tjonneland A, Thomsen BL, Christensen J, Loft S, Friedenreich C, Key TJ, Allen NE, Lahmann PH, Mejlvig L, Overvad K, Kaaks R, Rohrmann S, Boing H, Misirli G, Trichopoulou A, Zylis D, Tumino R, Pala V, Bueno-de-Mesquita HB, Kiemeney LA, Suarez LR, Gonzalez CA, Sanchez MJ, Huerta JM, Gurrea AB, Manjer J, Wirfalt E, Khaw KT, Wareham N, Boffetta P, Egevad L, Rinaldi S, Riboli E. Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Int J Cancer 2009; 125: 902-8.

212. Jaraj SJ, Camparo P, Boyle H, Germain F, Nilsson B, Petersson F, Egevad L. Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer. Virchows Arch 2009; 455: 375-81.

213. Helpap B, Egevad L. Modified Gleason grading. An updated review. Histol Histopathol 2009; 24: 661-6.

214. Helpap B, Egevad L. [Clinical insignificance of prostate cancer: are there morphological findings?]. Urologe A 2009; 48: 170-4.

215. Egevad L, Hakansson U, Grabe M, Ehrnstrom R. Urachal signet-cell adenocarcinoma. Scand J Urol Nephrol 2009; 43: 88-91.

216. Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Griffiths DF, Lopez-Beltran A, Mikuz G, Varma M, Montironi R, European Network of U. The European Network of Uropathology: a novel mechanism for communication between pathologists. Anal Quant Cytol Histol 2009; 31: 90-5.

217. Egevad L. Editorial comment on: Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol 2009; 55: 403.

218. Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, Mancini G, Lutz B, Bergh A, Fowler CJ. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009; 45: 174-82.

219. Buchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, Raaschou-Nielsen O, Tjonneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Chang-Claude J, Kaaks R, Boeing H, Weikert S, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Vineis P, Tumino R, Panico S, Vrieling A, Peeters PH, van Gils CH, Lund E, Gram IT, Engeset D, Martinez C, Gonzalez CA, Larranaga N, Ardanaz E, Navarro C, Rodriguez L, Manjer J, Ehrnstrom RA, Hallmans G, Ljungberg B, Allen NE, Roddam AW, Bingham S, Khaw KT, Slimani N, Boffetta P, Jenab M, Mouw T, Michaud DS, Kiemeney LA, Riboli E. Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2009; 125: 2643-51.

220. Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, Ostman A. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A 2009; 106: 3414-9.

221. Rubio CA, Orrego A, Hoog A, Porwitz A, Petersson F, Elmberger G, Glaessgen A, Eriksson E, Kanter L, Jaremko G, Egevad L, Laforga J, Liljefors M, Lofdahl B, Norman P, Larsson O, Wanat R, Wejde J, Zickert P, Bjork J, Caini S, Palli D, Nesi G. Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis. Am J Clin Pathol 2008; 130: 375-81.

222. Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kalkner KM, Nilsson S, Valdman A, Ullen A. Current status of prognostic immunohistochemical markers for urothelial bladder cancer. Tumour Biol 2008; 29: 311-22.

223. Rohrmann S, Linseisen J, Key TJ, Jensen MK, Overvad K, Johnsen NF, Tjonneland A, Kaaks R, Bergmann MM, Weikert C, Naska A, Trichopoulou A, Trichopoulos D, Pala V, Sacerdote C, Palli D, Tumino R, Bueno-de-Mesquita HB, Vrieling A, Gonzalez CA, Larranaga N, Navarro C, Barricarte A, Quiros JR, Martinez-Garcia C, Hallmans G, Stattin P, Manjer J, Wirfalt E, Bingham S, Khaw KT, Egevad L, Ferrari P, Jenab M, Riboli E. Alcohol consumption and the risk for prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2008; 17: 1282-7.

224. Lopez-Beltran A, Kirkali Z, Cheng L, Egevad L, Regueiro JC, Blanca A, Montironi R. Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Semin Diagn Pathol 2008; 25: 232-44.

225. Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, Reuter VE, Sakr WA, Srigley JR, Wheeler TM, Yang XJ, Epstein JI. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol 2008; 32: 1532-9.

226. Jonmarker S, Glaessgen A, Culp WD, Pisa P, Lewensohn R, Ekman P, Valdman A, Egevad L. Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS 2008; 116: 491-8.

227. Johansson M, Appleby PN, Allen NE, Travis RC, Roddam AW, Egevad L, Jenab M, Rinaldi S, Kiemeney LA, Bueno-de-Mesquita HB, Vollset SE, Ueland PM, Sanchez MJ, Quiros JR, Gonzalez CA, Larranaga N, Chirlaque MD, Ardanaz E, Sieri S, Palli D, Vineis P, Tumino R, Linseisen J, Kaaks R, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Khaw KT, Bingham S, Hallmans G, Riboli E, Stattin P, Key TJ. Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev 2008; 17: 279-85.

228. Helpap B, Egevad L. Correlation of modified Gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens. Anal Quant Cytol Histol 2008; 30: 133-8.

229. Helpap B, Egevad L. Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy. Anal Quant Cytol Histol 2008; 30: 1-7.

230. Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, Ekman P, Valdman A, Egevad L. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS 2008; 116: 888-95.

231. Evans AJ, Henry PC, Van der Kwast TH, Tkachuk DC, Watson K, Lockwood GA, Fleshner NE, Cheung C, Belanger EC, Amin MB, Boccon-Gibod L, Bostwick DG, Egevad L, Epstein JI, Grignon DJ, Jones EC, Montironi R, Moussa M, Sweet JM, Trpkov K, Wheeler TM, Srigley JR. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol 2008; 32: 1503-12.

232. Egevad L, Carbin BE, Castellanos E, Hellstrom M, Valdman A. Atypical stromal hyperplasia of the prostate. Scand J Urol Nephrol 2008; 42: 484-7.

233. Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Griffiths DF, Lopez-Beltran A, Mikuz G, Varma M, Montironi R, European Network of U. Handling and reporting of radical prostatectomy specimens in Europe: a web-based survey by the European Network of Uropathology (ENUP). Histopathology 2008; 53: 333-9.

234. Egevad L. Recent trends in gleason grading of prostate cancer. II. Prognosis, reproducibility and reporting. Anal Quant Cytol Histol 2008; 30: 254-60.

235. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol 2008; 30: 190-8.

236. Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 2008; 101: 293-8.

237. Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, Egevad L, Gann PH, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjonneland A, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Sieri S, Vineis P, Palli D, Quiros JR, Ardanaz E, Chirlaque MD, Larranaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Bikou C, Trichopoulos D, Stattin P, Jenab M, Ferrari P, Slimani N, Riboli E, Kaaks R. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121: 1331-8.

238. Ryden L, Egevad L, Ekman P, Hellstrom M. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies. Scand J Urol Nephrol 2007; 41: 302-7.

239. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P, Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quiros JR, Gonzalez CA, Martinez C, Larranaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 2007; 86: 672-81.

240. Helpap B, Egevad L. [The value of the modified Gleason grading system of prostate adenocarcinoma in routine urological diagnostics]. Urologe A 2007; 46: 59-62.

241. Hellstrom M, Lexander H, Franzen B, Egevad L. Proteomics in prostate cancer research. Anal Quant Cytol Histol 2007; 29: 32-40.

242. Hellstrom M, Jonmarker S, Lehtio J, Auer G, Egevad L. Proteomics in clinical prostate research. Proteomics Clin Appl 2007; 1: 1058-65.

243. Eriksson F, Culp WD, Massey R, Egevad L, Garland D, Persson MA, Pisa P. Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol Immunother 2007; 56: 677-87.

244. Egevad L, Ehrnstrom R, Hakansson U, Grabe M. Primary seminal vesicle carcinoma detected at transurethral resection of prostate. Urology 2007; 69: 778 e11-3.

245. Egevad L. Editorial comment on: Immunohistochemical expression of endothelin-1 and endothelin-a and endothelin-b receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol 2007; 52: 1689-90.

246. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjonneland A, Gronbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quiros JR, Ardanaz E, Navarro C, Larranaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the

European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007; 16: 1121-7.

247. Algaba F, Mikuz G, Boccon-Gibod L, Trias I, Arce Y, Montironi R, Egevad L, Scarpelli M, Lopez-Beltran A. Pseudoneoplastic lesions of the testis and paratesticular structures. Virchows Arch 2007; 451: 987-97.

248. Valdman A, Jonmarker S, Ekman P, Egevad L. Cytological features of prostatic intraepithelial neoplasia. Diagn Cytopathol 2006; 34: 317-22.

249. Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, Pisa P. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398-405.

250. Lexander H, Palmberg C, Hellman U, Auer G, Hellstrom M, Franzen B, Jornvall H, Egevad L. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics 2006; 6: 4370-80.

251. Lexander H, Hellman U, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H, Egevad L. Evaluation of two sample preparation methods for prostate proteome analysis. Proteomics 2006; 6: 3918-25.

252. Jonmarker S, Valdman A, Lindberg A, Hellstrom M, Egevad L. Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Arch 2006; 449: 297-301.

253. Helpap B, Egevad L. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 2006; 449: 622-7.

254. Glaessgen A, Busch C, Norberg M, Haggman M, Nilsson B, Egevad L. Prediction of percent Gleason grade 4/5 by multiple core biopsies. Scand J Urol Nephrol 2006; 40: 465-71.

255. Fang X, Liu Z, Fan Y, Zheng C, Nilson S, Egevad L, Ekman P, Xu D. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer 2006; 118: 2485-9.

256. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006; 13: 57-9.

257. Egevad L, Allsbrook WC, Jr., Epstein JI. Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists. Hum Pathol 2006; 37: 292-7.

258. Egevad L, Allsbrook WC, Epstein JI. Current practice of diagnosis and reporting of prostatic intraepithelial neoplasia and glandular atypia among genitourinary pathologists. Mod Pathol 2006; 19: 180-5.

259. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol 2006; 30: 1281-91.

260. Culp WD, Neal R, Massey R, Egevad L, Pisa P, Garland D. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res 2006; 5: 1332-43.

261. Valdman A, Fang X, Pang ST, Nilsson B, Ekman P, Egevad L. Ezrin expression in prostate cancer and benign prostatic tissue. Eur Urol 2005; 48: 852-7.

262. Srigley JR, Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Wheeler TM, Montironi R. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl 2005: 8-19.

263. Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005; 62: 217-23.

264. Ozenci V, Miller AM, Palmborg A, Egevad L, Jaremko GA, Kalkner KM, Pisa P. Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer. Prostate 2005; 65: 20-6.

265. Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005; 62: 394-9.

266. Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H, Egevad L. Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 2005; 27: 263-72.

267. Lexander H, Franzen B, Hirschberg D, Becker S, Hellstrom M, Bergman T, Jornvall H, Auer G, Egevad L. Differential protein expression in anatomical zones of the prostate. Proteomics 2005; 5: 2570-6.

268. Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 2005; 48: 577-83.

269. Haggarth L, Busch C, Norberg M, Haggman M, Norlen BJ, Egevad L. Prediction of the volume of large prostate cancers by multiple core biopsies. Scand J Urol Nephrol 2005; 39: 380-6.

270. Haggarth L, Auer G, Busch C, Norberg M, Haggman M, Egevad L. The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer. Scand J Urol Nephrol 2005; 39: 387-92.

271. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005: 34-63.

272. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42.

273. Egevad L, Allsbrook WC, Jr., Epstein JI. Current practice of Gleason grading among genitourinary pathologists. Hum Pathol 2005; 36: 5-9.

274. Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005: 20-33.

275. Valdman A, Fang X, Pang ST, Ekman P, Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 2004; 60: 367-71.

276. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91: 688-94.

277. Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L, Ekman P. Expression of ezrin in prostatic intraepithelial neoplasia. Urology 2004; 63: 609-12.

278. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004; 101: 811-6.

279. Key TJ, Allen N, Appleby P, Overvad K, Tjonneland A, Miller A, Boeing H, Karalis D, Psaltopoulou T, Berrino F, Palli D, Panico S, Tumino R, Vineis P, Bueno-De-Mesquita HB, Kiemeney L, Peeters PH, Martinez C, Dorronsoro M, Gonzalez CA, Chirlaque MD, Quiros JR, Ardanaz E, Berglund G, Egevad L, Hallmans G, Stattin P, Bingham S, Day N, Gann P, Kaaks R, Ferrari P, Riboli E, European Prospective Investigation into C, Nutrition. Fruits and vegetables and prostate cancer: no association among 1104 cases in a prospective study of 130544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004; 109: 119-24.

280. Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L. Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens. Virchows Arch 2004; 445: 17-21.

281. Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L. Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies. J Urol 2004; 171: 664-7.

282. Shiao YH, Forsti A, Egevad L, Anderson LM, Lindblad P, Hemminki K. VHL down-regulation and differential localization as mechanisms in tumorigenesis. Kidney Int 2003; 64: 1671-4.

283. Richardsen E, Ukkonen T, Bjornsen T, Mortensen E, Egevad L, Busch C. Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium. Virchows Arch 2003; 442: 329-35.

284. Egevad L. Cytology of the central zone of the prostate. Diagn Cytopathol 2003; 28: 239-44.

285. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002; 51: 268-75.

286. Sahlen GE, Egevad L, Ahlander A, Norlen BJ, Ronquist G, Nilsson BO. Ultrastructure of the secretion of prostasomes from benign and malignant epithelial cells in the prostate. Prostate 2002; 53: 192-9.

287. Hemminki K, Jiang Y, Ma X, Yang K, Egevad L, Lindblad P. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Carcinogenesis 2002; 23: 809-15.

288. Haggarth L, Ekman P, Egevad L. A new core-biopsy instrument with an end-cut technique provides prostate biopsies with increased tissue yield. BJU Int 2002; 90: 51-5.

289. Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L. Interobserver reproducibility of percent Gleason grade 4/5 in total prostatectomy specimens. J Urol 2002; 168: 2006-10.

290. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J Urol 2002; 168: 509-13.

291. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002; 89: 538-42.

292. Soderstrom TG, Bjelfman C, Brekkan E, Ask B, Egevad L, Norlen BJ, Rane A. Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 2001; 86: 855-8.

293. Ma X, Yang K, Lindblad P, Egevad L, Hemminki K. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium. Oncogene 2001; 20: 5393-400.

294. Frimmel H, Egevad L, Busch C, Bengtsson E. Automatic registration and error detection of multiple slices using landmarks. Anal Cell Pathol 2001; 23: 159-65.

295. Finnstrom N, Bjelfman C, Soderstrom TG, Smith G, Egevad L, Norlen BJ, Wolf CR, Rane A. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur J Clin Invest 2001; 31: 880-6.

296. Egevad L, Norlen BJ, Norberg M. The value of multiple core biopsies for predicting the Gleason score of prostate cancer. BJU Int 2001; 88: 716-21.

297. Egevad L. Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images. Urology 2001; 57: 291-5.

298. Andersson J, Ekman P, Egevad L, Hellstrom M. Relatively high risk of treatment failure after prostatectomy: tumour grade, histopathological stage and the preoperative serum PSA level are key prognosticators. Scand J Urol Nephrol 2001; 35: 453-8.

299. Alaiya AA, Oppermann M, Langridge J, Roblick U, Egevad L, Brindstedt S, Hellstrom M, Linder S, Bergman T, Jornvall H, Auer G. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci 2001; 58: 307-11.

300. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 1910-7.

301. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000; 17: 445-51.

302. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, Huwendiek S, Linder S, Auer G. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000; 21: 1-9.

303. Yang K, Lindblad P, Egevad L, Hemminki K. Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas. Cancer Lett 1999; 141: 1-8.

304. Nilsson BO, Egevad L, Jin M, Ronquist G, Busch C. Distribution of prostasomes in neoplastic epithelial prostate cells. Prostate 1999; 39: 36-40.

305. Frimmel H, Egevad L, Bengtsson E, Busch C. Modeling prostate cancer distributions. Urology 1999; 54: 1028-34.

306. Egevad L, Frimmel H, Norberg M, Mattson S, Carlbom I, Bengtsson E, Busch C. Three-dimensional computer reconstruction of prostate cancer from radical prostatectomy specimens: evaluation of the model by core biopsy simulation. Urology 1999; 53: 192-8.

307. Egevad L, Frimmel H, Mattson S, Bengtsson E, Busch C. Biopsy protocol stability in a three-dimensional model of prostate cancer: changes in cancer yield after adjustment of biopsy positions. Urology 1999; 54: 862-8.

308. Egevad L, Engström K, Mattson S, Wester K, Busch C. Heterogeneity of DNA ploidy in prostate cancer. Journal of Urologic Pathology 1999; 10: 23-37.

309. Loughlin M, Carlbom I, Busch C, Douglas T, Egevad L, Frimmel H, Norberg M, Sesterhenn I, Frogge JM. Three-dimensional modeling of biopsy protocols for localized prostate cancer. Comput Med Imaging Graph 1998; 22: 229-38.

310. Egevad L, Norberg M, Mattson S, Norlen BJ, Busch C. Estimation of prostate cancer volume by multiple core biopsies before radical prostatectomy. Urology 1998; 52: 653-8.

311. Egevad L, Engström K, Busch C. A new method for handling radical prostatectomies enabling fresh tissue harvesting, whole mount sections and landmarks for alignment of sections. . Journal of Urologic Pathology 1998; 9: 17-28.

312. Busch PC, Egevad L, Haggman M. Precancer of the prostate. Cancer Surv 1998; 32: 149-79.

313. Sundstrom C, Egevad L. [More pathologists are needed in Sweden! Retirements may cause a real crisis]. Lakartidningen 1997; 94: 2443.

314. Ranefall P, Egevad L, Nordin B, Bengtsson E. A new method for segmentation of colour images applied to immunohistochemically stained cell nuclei. Anal Cell Pathol 1997; 15: 145-56.

315. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50: 562-6.

316. Ljung G, Egevad L, Norberg M, Holmberg L, Nilsson S, Busch C. Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. Prostate 1997; 32: 99-105.

317. Bjelfman C, Soderstrom TG, Brekkan E, Norlen BJ, Egevad L, Unge T, Andersson S, Rane A. Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 1997; 82: 2210-4.

318. Norberg M, Holmberg L, Busch C, Haggman M, Egevad L, Magnusson A. Multiple transrectal ultrasound-guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion. Eur Radiol 1996; 6: 56-61.

319. Ljung G, Egevad L, Norberg M, de la Torre M, Holmberg L, Busch C, Nilsson S. Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy. Prostate 1996; 29: 303-10.

320. Ljung G, Norberg M, Hansson H, de la Torre M, Egevad L, Holmberg L, Busch C, Nilsson S. Transrectal ultrasonically-guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Acta Oncol 1995; 34: 945-52.